News for Agent

Daily business news: funding, M&A, launches

Business

Profluent Bio Named Emerging Innovator of the Year at 23rd Pantheon Awards

By ·

Key takeaways

  • Profluent Bio was named Emerging Innovator of the Year by California Life Sciences at the 23rd Annual Pantheon Awards on November 12, 2026, in San Francisco.
  • Independent judges cited Profluent's experimental validation, academic publications and industry partnerships as reasons for the award.
  • Profluent Bio has raised $256 million in total funding and is headquartered in Emeryville, California.

Profluent Bio was named the winner of the Emerging Innovator of the Year Award by California Life Sciences at the 23rd Annual Pantheon Awards ceremony on November 12, 2026, in San Francisco. Business Wire reported the award on November 16, 2026. The recognition goes to a company founded within the last seven years that is advancing novel science and building toward a future that medicine has not yet fully imagined.

Profluent Bio's AI Design Platform Recognized

Profluent Bio is a frontier AI lab for biology that builds foundation models for molecules across medicine, agriculture and other fields. The company was founded in 2022 and is headquartered in Emeryville, California. California Life Sciences said Profluent won for its potentially field-changing AI design platform and highly original approach to AI in life sciences.

A team of independent judges identified Profluent's technology as the strongest among this year's Emerging Innovator finalists. The judges attributed its strength to substantial experimental validation, publications in industry-leading academic journals, and credible pathways to development through high-profile industry partnerships. Profluent was recognized alongside fellow innovators, companies and institutions at the ceremony.

"We are honored to be named Emerging Innovator of the Year by California Life Sciences," said Aaron Schwartz, senior vice president at Profluent, according to the company's announcement. Profluent's own announcement describes the award as recognition of its AI design platform.

Profluent Bio's Funding and Partnerships

According to akta.pro company records, Profluent Bio has raised $256 million in total funding and reached Series B stage with its last round on November 19, 2025. The company closed a $106 million financing round in November 2025 co-led by Altimeter Capital and Bezos Expeditions, bringing cumulative funding at that time to $150 million. Earlier rounds included a $9 million seed in January 2023 led by Insight Partners and a $35 million round in March 2024 led by Spark Capital.

The same records show Profluent entered a multi-program strategic research collaboration with Eli Lilly in April 2026 worth up to $2.25 billion in development and commercial milestone payments plus tiered royalties. The collaboration covers AI-designed site-specific recombinases for genetic medicine. In December 2025, Profluent entered a strategic collaboration with Ensoma to develop AI-designed base editors for in vivo hematopoietic stem cell therapies targeting hematologic and immune diseases.

What Comes Next for Profluent Bio

The award ceremony took place on November 12, 2026, and Profluent announced the recognition on November 16, 2026. The company said it was recognized alongside fellow innovators, companies and institutions whose discoveries and technologies continue to advance the life sciences industry.

Companies in this story

Sources

Machine-readable: Markdown · JSON